Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + NTX-301|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|NTX-301||NTX 301|NTX301||DNMT1 inhibitor 4||NTX-301 inhibits DNMT1, potentially leading to reduced tumor growth and improved survival (PMID: 35410412; J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7077).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04851834||Phase Ib/II||Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301||NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma||Terminated||AUS||0|